Silperisone: a centrally acting muscle relaxant

Area of Science:

• Pharmacology
• Neuroscience
• Drug Development

Background:

• Silperisone is an organosilicon compound with centrally acting muscle relaxant properties, similar to tolperisone.
• Preclinical studies suggested potential for reduced central nervous system (CNS) depressant and motor side effects compared to existing antispastic drugs.

Purpose of the Study:

• To evaluate the efficacy and safety of silperisone as a centrally acting muscle relaxant and antispastic agent.
• To compare the pharmacological profile and pharmacokinetic properties of silperisone with tolperisone and eperisone.

Main Methods:

• In vivo and in vitro studies in animal models (mice, rats, cats) to assess effects on spinal reflexes and decerebrate rigidity.
• Pharmacokinetic assessments including absorption, metabolism, bioavailability, and elimination half-life in various species, including humans.
• Phase I clinical trials to evaluate safety and tolerability at effective preclinical doses.

Main Results:

• Silperisone effectively suppressed spinal reflexes and decerebrate rigidity in animal models.
• It demonstrated longer duration of action and higher oral bioavailability than tolperisone and eperisone in certain species.
• Mechanism involves blockade of voltage-gated sodium and calcium channels, and a stronger potassium channel blocking effect than tolperisone.
• Phase I studies showed no adverse effects at effective doses, but chronic animal toxicity studies halted development.

Conclusions:

• Silperisone exhibited favorable muscle relaxant and antispastic properties with a potentially improved side effect profile.
• Its pharmacokinetic advantages and demonstrated efficacy suggested therapeutic potential.
• Despite promising early clinical findings, safety concerns from chronic animal toxicity studies ultimately led to the discontinuation of its development.